Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Rigel Pharmaceuticals (Nasdaq: RIGL) announced inducement awards under Nasdaq Listing Rule 5635(c)(4) dated April 7, 2026.
Rhea-AI Summary
Rigel Pharmaceuticals (Nasdaq: RIGL) announced inducement awards under Nasdaq Listing Rule 5635(c)(4) dated April 7, 2026. The company granted 8,925 restricted stock units to six non-executive employees that vest over four years, with 25% vesting each year.
This action was approved by Rigel's Compensation Committee and issued as inducements for new employees joining the company.
Positive
- None.
Negative
- None.
Details
News Market Reaction – RIGL
In the Apr 7 session, RIGL gained 5.01%, reflecting a notable positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
- Inducement RSUs
- 8,925 units
- Granted to new non-executive employees under Inducement Plan
- Employees granted
- 6 employees
- Non-executive hires receiving inducement RSU awards
- Vesting period
- 4 years
- RSUs vest over four years as part of employment inducement
- Annual vesting rate
- 25% per year
- One-quarter of each RSU grant vests annually
- Founding year
- 1996
- Year Rigel Pharmaceuticals, Inc. was founded
- Listing rule
- 5635(c)(4)
- NASDAQ Listing Rule governing inducement equity grants
Historical Context
-
Final Phase 1/2 ARROW data for GAVRETO in RET+ NSCLC published.
-
Strong Q4 and 2025 revenue, net income, and 2026 guidance released.
-
Announcement of schedule for Q4 and full-year 2025 results call.
-
Appointment of Michael P. Miller to the Board of Directors.
-
First patient enrolled in Phase 1b/2 REZLIDHIA AML combination trial.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
restricted stock units financial
inducement plan financial
nasdaq listing rule 5635(c)(4) regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
About Rigel
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. Founded in 1996, Rigel is based in
Contact for Investors & Media
Rigel Pharmaceuticals, Inc.
650.624.1232
ir@rigel.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/rigel-pharmaceuticals-inc-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-302735168.html
SOURCE Rigel Pharmaceuticals, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
